TPI 1020

Drug Profile

TPI 1020

Alternative Names: NCX 1020; NO-budesonide; TPI-1020

Latest Information Update: 14 Jan 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NicOx
  • Developer NicOx; Topigen Pharmaceuticals
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Immunosuppressants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 14 Jan 2010 Discontinued - Phase-II for Asthma in Canada (Inhalation)
  • 14 Jan 2010 Discontinued - Phase-II for Asthma in Europe (Inhalation)
  • 16 Sep 2009 Preclinical pharmacodynamics data in Bronchial disorders presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top